Immix Biopharma Stock (NASDAQ:IMMX)

Forecast Revenue Ownership Financials Chart

Previous Close

$2.22

52W Range

$1.26 - $7.50

50D Avg

$1.82

200D Avg

$2.12

Market Cap

$59.69M

Avg Vol (3M)

$177.53K

Beta

0.10

Div Yield

IMMX Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 16, 2021

Website

IMMX Performance

IMMX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$-89.52M	-
Operating Income	$-16.14M	$-8.22M	$-1.35M
Net Income	$-15.43M	$-8.23M	$-24.38M
EBITDA	$-16.14M	$-8.22M	$-1.35M
Basic EPS	$-0.89	$-0.62	$-6.64
Diluted EPS	$-0.89	$-0.59	$-6.64

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
CNSP	CNS Pharmaceuticals, Inc.
ELEV	Elevation Oncology, Inc.
OCEA	Ocean Biomedical, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
ENVB	Enveric Biosciences, Inc.